JP2022088597A5 - - Google Patents

Download PDF

Info

Publication number
JP2022088597A5
JP2022088597A5 JP2022058938A JP2022058938A JP2022088597A5 JP 2022088597 A5 JP2022088597 A5 JP 2022088597A5 JP 2022058938 A JP2022058938 A JP 2022058938A JP 2022058938 A JP2022058938 A JP 2022058938A JP 2022088597 A5 JP2022088597 A5 JP 2022088597A5
Authority
JP
Japan
Prior art keywords
human
human immunoglobulin
light chain
nucleic acid
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022058938A
Other languages
English (en)
Japanese (ja)
Other versions
JP7274018B2 (ja
JP2022088597A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/035731 external-priority patent/WO2017210586A1/en
Application filed filed Critical
Publication of JP2022088597A publication Critical patent/JP2022088597A/ja
Publication of JP2022088597A5 publication Critical patent/JP2022088597A5/ja
Priority to JP2023074624A priority Critical patent/JP7586960B2/ja
Application granted granted Critical
Publication of JP7274018B2 publication Critical patent/JP7274018B2/ja
Priority to JP2024195337A priority patent/JP7805430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022058938A 2016-06-03 2022-03-31 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物 Active JP7274018B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023074624A JP7586960B2 (ja) 2016-06-03 2023-04-28 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物
JP2024195337A JP7805430B2 (ja) 2016-06-03 2024-11-07 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662345524P 2016-06-03 2016-06-03
US62/345,524 2016-06-03
PCT/US2017/035731 WO2017210586A1 (en) 2016-06-03 2017-06-02 Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
JP2018563156A JP7053499B2 (ja) 2016-06-03 2017-06-02 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018563156A Division JP7053499B2 (ja) 2016-06-03 2017-06-02 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023074624A Division JP7586960B2 (ja) 2016-06-03 2023-04-28 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物

Publications (3)

Publication Number Publication Date
JP2022088597A JP2022088597A (ja) 2022-06-14
JP2022088597A5 true JP2022088597A5 (enExample) 2023-01-18
JP7274018B2 JP7274018B2 (ja) 2023-05-15

Family

ID=59215996

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018563156A Active JP7053499B2 (ja) 2016-06-03 2017-06-02 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物
JP2022058938A Active JP7274018B2 (ja) 2016-06-03 2022-03-31 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物
JP2023074624A Active JP7586960B2 (ja) 2016-06-03 2023-04-28 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物
JP2024195337A Active JP7805430B2 (ja) 2016-06-03 2024-11-07 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018563156A Active JP7053499B2 (ja) 2016-06-03 2017-06-02 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023074624A Active JP7586960B2 (ja) 2016-06-03 2023-04-28 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物
JP2024195337A Active JP7805430B2 (ja) 2016-06-03 2024-11-07 外因性ターミナルデオキシヌクレオチジルトランスフェラーゼを発現する非ヒト動物

Country Status (26)

Country Link
US (3) US10980221B2 (enExample)
EP (3) EP4218408B1 (enExample)
JP (4) JP7053499B2 (enExample)
KR (3) KR102784608B1 (enExample)
CN (3) CN113907043B (enExample)
AU (2) AU2017272337C1 (enExample)
BR (1) BR112018074794A2 (enExample)
CA (1) CA3026088A1 (enExample)
CY (1) CY1126063T1 (enExample)
DK (2) DK4218408T3 (enExample)
ES (2) ES3018427T3 (enExample)
FI (2) FI3462853T3 (enExample)
HR (2) HRP20230497T1 (enExample)
HU (2) HUE061619T2 (enExample)
IL (2) IL263160B2 (enExample)
LT (2) LT4218408T (enExample)
MX (3) MX385681B (enExample)
NZ (1) NZ788750A (enExample)
PL (2) PL3462853T3 (enExample)
PT (2) PT4218408T (enExample)
RS (2) RS66700B1 (enExample)
RU (1) RU2753585C2 (enExample)
SG (2) SG10201914014XA (enExample)
SI (2) SI3462853T1 (enExample)
SM (2) SMT202500152T1 (enExample)
WO (1) WO2017210586A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110192541B (zh) 2013-02-22 2022-02-18 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
SI3462853T1 (sl) 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
LT3720279T (lt) 2017-12-05 2022-10-25 Regeneron Pharmaceuticals, Inc. Pelės, turinčios sukonstruotą imunoglobulino lambda lengvąją grandinę, ir jų panaudojimas
HUE070158T2 (hu) * 2018-03-24 2025-05-28 Regeneron Pharma Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk
US20210238312A1 (en) * 2018-06-13 2021-08-05 The Children's Medical Center Corporation Methods and compositions relating to high-throughput models for antibody discovery and/or optimization
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
SG11202107589PA (en) * 2019-02-22 2021-08-30 Regeneron Pharma Rodents having genetically modified sodium channels and methods of use thereof
MX2021014893A (es) 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
IL293820A (en) * 2019-12-12 2022-08-01 Dna Script Chimeric-terminal deoxynucleotidyltransferases for template-independent enzymatic synthesis of polynucleotides
CN111057754B (zh) * 2019-12-27 2021-01-12 四川省医学科学院.四川省人民医院实验动物研究所 鉴定适用于hbv研究的动物模型的方法和应用
US12250931B2 (en) 2020-01-28 2025-03-18 Regeneron Pharmaceuticals, Inc. Genetically modified mouse with a humanized PNPLA3 gene and methods of use
JP7765403B2 (ja) * 2020-04-21 2025-11-06 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US20240317849A1 (en) 2020-12-23 2024-09-26 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
AU2022249328A1 (en) * 2021-03-31 2023-09-21 Regeneron Pharmaceuticals, Inc. Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
KR20250077529A (ko) * 2022-09-22 2025-05-30 리제너론 파아마슈티컬스, 인크. 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
CN120099099A (zh) * 2024-03-05 2025-06-06 百奥赛图(北京)医药科技股份有限公司 一种trbc基因修饰的非人动物
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof
WO2026035843A2 (en) 2024-08-06 2026-02-12 Regeneron Pharmaceuticals, Inc. Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9119338D0 (en) 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
US6001349A (en) 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US6770291B2 (en) 1996-08-30 2004-08-03 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6749863B1 (en) 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2440676A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transgenic animals expressing antibodies specific for genes of interest and uses thereof
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1575601B1 (en) 2002-12-16 2015-07-01 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant vaccine viruses expressing il-15 and methods of using the same
WO2004067753A2 (en) 2003-01-28 2004-08-12 Cellectis Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof.
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
US8218805B2 (en) 2003-10-11 2012-07-10 Charles Hornback Wireless speaker system for use with ceiling fans
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
US20060222653A1 (en) 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants
US20060275282A1 (en) 2005-01-12 2006-12-07 Xencor, Inc. Antibodies and Fc fusion proteins with altered immunogenicity
CA2616069C (en) * 2005-08-03 2018-07-31 Therapeutic Human Polyclonals, Inc. Suppression of b-cell apoptosis in transgenic animals expressing humanized immunoglobulin
WO2007022520A2 (en) 2005-08-19 2007-02-22 Cerus Corporation Antibody-mediated enhancement of immune response
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
KR102096731B1 (ko) 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
US7867483B2 (en) 2007-10-18 2011-01-11 Bn Immunotherapeutics, Inc. Use of MVA to treat prostate cancer
US8225343B2 (en) 2008-01-11 2012-07-17 Sony Computer Entertainment America Llc Gesture cataloging and recognition
PT3456190T (pt) 2008-06-27 2022-02-15 Merus Nv Animal murino transgénico produtor de anticorpo
KR101987351B1 (ko) 2008-09-30 2019-06-10 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
US8691502B2 (en) 2008-10-31 2014-04-08 Tremrx, Inc. T-cell vaccination with viral vectors via mechanical epidermal disruption
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011072204A1 (en) 2009-12-10 2011-06-16 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
MX341925B (es) 2010-03-29 2016-09-07 Zymeworks Inc Anticuerpos con funcion efectora suprimida o mejorada.
KR101830020B1 (ko) 2010-03-31 2018-02-19 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
SG10201504568YA (en) 2010-06-22 2015-07-30 Regeneron Pharma Hybrid light chain mice
DK2597945T3 (da) 2010-07-26 2020-09-21 Trianni Inc Transgene dyr og fremgangsmåder til anvendelse deraf
EP3960865A1 (en) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
ME03732B (me) 2011-02-25 2021-01-20 Regeneron Pharma Miševi s ADAM6
JP5893258B2 (ja) 2011-03-31 2016-03-23 フェリカネットワークス株式会社 情報処理装置および方法、並びにプログラム
US20130018582A1 (en) 2011-07-13 2013-01-17 Miller Paul A Inertial Navigation Common Azimuth Reference Determination System and Method
HRP20192255T1 (hr) 2011-08-05 2020-03-06 Regeneron Pharmaceuticals, Inc. Humanizirani miševi s univerzalnim lakim lancem
BR112014006390A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
HRP20220253T1 (hr) 2011-10-17 2022-04-29 Regeneron Pharmaceuticals, Inc. Miševi s ograničenim teškim lancem imunoglobulina
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
CN114891797A (zh) 2011-10-28 2022-08-12 瑞泽恩制药公司 T细胞受体基因修饰小鼠
RS56656B1 (sr) 2011-10-28 2018-03-30 Regeneron Pharma Miševi sa genetski modifikovanim glavnim kompleksom gena tkivne podudarnosti
RS56330B1 (sr) 2011-10-28 2017-12-29 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
MY186903A (en) 2011-10-28 2021-08-26 Regeneron Pharma Humanized il-6 and il-6 receptor
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9120662B2 (en) 2011-11-14 2015-09-01 Susan A. Thomson Gathering and dispensing scoop with gate valve
US9547499B2 (en) 2011-12-09 2017-01-17 Microsoft Technology Licensing, Llc Device configuration with cached pre-assembled driver state
RU2014141536A (ru) 2012-03-16 2016-05-10 Регенерон Фармасьютикалз, Инк. Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания
PT2825037T (pt) 2012-03-16 2019-08-07 Regeneron Pharma Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph
SMT201800395T1 (it) 2012-03-16 2018-09-13 Regeneron Pharma Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
JP5920830B2 (ja) 2012-09-28 2016-05-18 シスメックス株式会社 試料調製装置および細胞分析装置
EP4269602A3 (en) 2012-12-14 2023-12-27 OmniAB, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
KR20240147707A (ko) 2013-02-20 2024-10-08 리제너론 파아마슈티컬스, 인크. 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스
LT2840892T (lt) * 2013-02-20 2018-07-25 Regeneron Pharmaceuticals, Inc. Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis
CN110192541B (zh) 2013-02-22 2022-02-18 瑞泽恩制药公司 表达人源化主要组织相容性复合物的小鼠
CA2908697C (en) 2013-04-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US9783618B2 (en) * 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
SG10201808225TA (en) 2014-03-21 2018-10-30 Regeneron Pharma Non-human animals that make single domain binding proteins
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
HUE049776T2 (hu) 2014-06-06 2020-10-28 Regeneron Pharma Módszerek és készítmények egy célzott lókusz módosítására
HUE048677T2 (hu) * 2014-06-19 2020-07-28 Regeneron Pharma Humanizált programozott sejthalál 1 génnel rendelkezõ nem-humán állatok
MX384887B (es) 2014-06-23 2025-03-14 Regeneron Pharma Ensamblaje de adn mediado por nucleasa.
EP3161128B1 (en) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
WO2016044745A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
KR20240132525A (ko) 2015-04-06 2024-09-03 리제너론 파아마슈티컬스, 인크. 비인간 동물에서의 인간화 t 세포 매개 면역반응
SI3462853T1 (sl) 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo

Similar Documents

Publication Publication Date Title
JP2022088597A5 (enExample)
US20240057572A1 (en) Animal Models and Therapeutic Molecules
JP2018138047A5 (enExample)
JP2021137030A5 (enExample)
JP2025105667A5 (enExample)
JP2019083823A5 (enExample)
JP2010529042A5 (enExample)
HRP20170322T1 (hr) Miševi koji stvaraju vl vezne proteine
RU2014153673A (ru) Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина
JP2017509355A5 (enExample)
JP2014110814A5 (enExample)
JP2012532598A5 (enExample)
RU2016141307A (ru) Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
CA2532117A1 (en) Humanized immunoglobulin loci
RU2019112589A (ru) Отличные от человека животные со сконструированным локусом легкой лямбда-цепи иммуноглобулина
JP2011182801A5 (enExample)
JP2015502177A5 (enExample)
HUE029785T2 (en) Common light chain mouse
JP2015519055A5 (enExample)
HUE034386T2 (en) Production of binding molecules
JPWO2020169022A5 (enExample)
US20250234846A1 (en) Genetically modified non-human mammals, preparation methods therefor, and applications thereof
Vora et al. Altering the antibody repertoire via transgene homologous recombination: evidence for global and clone-autonomous regulation of antigen-driven B cell differentiation.
JPWO2021244522A5 (enExample)
JPWO2020247623A5 (enExample)